Table 2 Demographics of patients (MRI cohort)

From: FABP7 is increased in progressive multiple sclerosis and induces a pro-inflammatory phenotype in monocytes through a glycolytic switch

 

RRMS

SPMS

N

30

4

Mean age ( ± SD) in year

43.5 ( ± 9.3)

51.4 ( ± 11.6)

Female

19 (63.3%)

3 (75%)

Male

11 (36.7%)

1 (25%)

Relapsing MS

0

0

Remitting MS

30

0

Black or African American race

1

1

More than one race

2

0

White race

27

3

Anti-CD20

4

0

Dimethyl Fumarate

6

0

Fingolimod

6

0

Glatiramer Acetate

3

2

Interferon beta

2

0

Methotrexate

1

0

Mycophenolate Mofetil

1

1

Natalizumab

3

1

Untreated

4

0

  1. Anti-CD20, Dimethyl Fumarate, Fingolimod, Glatiramer Acetate, Interferon beta, Methotrexate, Mycophenolate Mofetil, and Natalizumab are categories of patients on those therapies. RRMS  Relapsing remitting MS, SPMS  Secondary progressive MS.
Back to article page